Pediatric Praziquantel Consortium

From the Program Lead: a strong finish to 2017

29 January 2018

Dr. Elly Kourany-Lefoll, Program Lead, explains why the Pediatric Praziquantel Consortium made a strong finish to 2017, and is ready to start 2018 with motivation and enthusiasm. 

Tackling neglected diseases to benefit Africa

29 January 2018

The ambitious African-led ‘Tackling Infections to Benefit Africa’ (TIBA) partnership has just been launched, and nine different Sub-Saharan African countries are starting work on initial one-year rapid impact projects. Professor Francisca Mutapi reflects on the importance of these projects that consider how diseases can be addressed in actual local health system settings. 

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana. 
Video credit: Shelly Xie

 

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that aims to use small, orally dispersible tablets with an acceptable taste. 

Read more